Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
Completed · Phase 1 · Has a placebo group
Conditions studied: Ebola Sudan Virus Disease
In brief
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
Key facts
- Study ID
- NCT05724472
- Run by
- International AIDS Vaccine Initiative
- People needed
- 36
- Starts
- 2023-06-19
- Expected to finish
- 2024-01-09
- Last updated by the study team
- 2024-11-06
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Benchmark Research — Austin, Texas, United States
- Clinical Trials of Texas — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.